Studying blood
Harnessing blood as the most data rich sample type.
Discovering
Discovering low abundance markers of disease
Developing
Developing assay against the most biologically significant markers of disease.
To achieve this breakthrough,
YYZ Pharmatech has created enabling technologies that overcome three fundamental challenges:
Harness blood as the most data rich sample type
Identify low-abundance markers of disease
Develop ultra-sensitive assays against the most biologically significant biomolecules
Platform
YYZ’s integrated technology platform identifies & quantifies low-abundance markers from blood. Supported by over 20 years of research & peer-reviewed publications, YYZ’s platform is powered by
Database-Driven Proteome Intact Partition Statistical Analysis
DPiPSA™ for Discovery
Discover low-abundance & biologically significant peptides & proteins from blood or other biological samples using an unbiased & statistically rigorous bioinformatics platform. DPiPSA’s innovation is based on the novel integration of optimized sample preparation, LC-MS/MS & classical statistics.
DPiPSA is:
- Unbiased
- Statistically Rigorous
- Complementary to “omic” Methods
Applications:
- Discover New Markers for Diagnostics & Prognostics
- Identify New Therapeutic Targets
- Identify Protein Modifications & Processing
- Enable Multi Centered Clinical Drug Trials
Enzyme Linked Mass Spectrometric Assay
ELiMSA™ for Measurement
Assay low-abundance biomolecules using a quantitative detection method that reaches single molecule level sensitivity. ELiMSA’s innovation is based on the novel combination of enzyme amplification & LC-MS/MS.
ELiMSA is:
- Ultra-Sensitive
- Versatile
- Easy to Execute
Applications:
- Circulating Proteins & Peptides
- Cell-Surface Receptors
- DNA
- RNA
Enzyme Linked Mass Spectrometric Assay
ELiMSA™ for Measurement
Assay low-abundance biomolecules using a quantitative detection method that reaches single molecule level sensitivity. ELiMSA’s innovation is based on the novel combination of enzyme amplification & LC-MS/MS.
ELiMSA is:
- Ultra-Sensitive
- Versatile
- Easy to Execute
Applications:
- Circulating Proteins & Peptides
- Cell-Surface Receptors
- DNA
- RNA
Company
YYZ Pharmatech is emerging from stealth after nearly two decades pushing the frontiers of the discovery & measurement of biomolecules.
Expertise
Commercialization partner of the Marshall Team at Toronto Metropolitan University. Dr. John G. Marshall is a leader in blood-based protein & ligand analytical biochemistry.
Endurance
YYZ Pharmatech is privately owned & based out of Toronto, Canada. Our investors specialize in building enabling technologies & are committed to long-term impact.
CollaborationToronto Metropolitan University spinout (formerly Ryerson University), with numerous clinical & academic partnerships.
Research & Publications
DPiPSA
Featured Publication
Neurology: Alzheimer’s Disease
- Striking agreement between the proteins known to be mutated or dis-regulated in the brains of AD patients and the proteins observed in the plasma of AD patients
- Novel factors and dysregulations discovered
Clinical Proteomics
The Plasma Peptidome
- Largest number of blood proteins identified to date
- Ability to monitor ex vivo proteolysis of most human proteins, including interleukins, from blood
Clinical Proteomics
Oncology: The Plasma Peptides of Breast Versus Ovarian Cancer
- Striking agreement between the breast cancer plasma peptides and proteins discovered by LC-ESI-MS/MS with previous biomarkers from tumors, cell lines or body fluids by genetic or biochemical methods
Clinical Proteomics
Blood Infection: The Plasma Peptides of Sepsis
- Disease association variation in the processing of SAA1 in sepsis patients
Clinical Proteomics
The Plasma Peptidome
- Largest number of blood proteins identified to date
- Ability to monitor ex vivo proteolysis of most human proteins, including interleukins, from blood
Clinical Proteomics
Oncology: The Plasma Peptides of Breast Versus Ovarian Cancer
- Striking agreement between the breast cancer plasma peptides and proteins discovered by LC-ESI-MS/MS with previous biomarkers from tumors, cell lines or body fluids by genetic or biochemical methods
Clinical Proteomics
Blood Infection: The Plasma Peptides of Sepsis
- Disease association variation in the processing of SAA1 in sepsis patients
Clinical Proteomics
Featured Publication
Neurology: Alzheimer’s Disease
- Striking agreement between the proteins known to be mutated or dis-regulated in the brains of AD patients and the proteins observed in the plasma of AD patients
- Novel factors and dysregulations discovered
Clinical Proteomics
Research & Publications
ELiMSA
Oncology Study: Analytical Advantage
- Absolute sensitivity to detect attomole of PSA
- Comparable sensitivity to RIA
- 1000-fold more sensitive than fluorescence detectors
Journal of Proteomics
Blinded Oncology Study 1: Predicate Agreement
- Excellent agreement with, but more sensitive than the present gold standard commercial fourescent ELISA, or ECL-based detection of PSA from normal and prostatectomy samples
Analytical and Bioanalytical Chemistry
Blinded Oncology Study 2: Clinical Advantage
- Routine analysis of proteins over the complete range of physiological concentrations
Analytical Biochemistry
Featured Publication
Quantitation at Single Molecule Level
- Linear measurement down to a single molecule per micro liter with approximately 10% error.
Journal of the American Society for Mass Spectrometry
Enabling the Next Generation of Medicine
Partnering with
YYZ Pharmatech
- YYZ was founded to enable & partner with visionary life science companies.
- Seeking collaboration opportunities on projects requiring:
- Novel low-abundance markers to progress drug development (i.e. identify novel cytokines, growth factors, hormones, chemokines, interleukins & tumor necrosis factors with DPiPSA)
- More sensitive measurement (i.e. characterize novel biotherapies acting at very low concentrations with ELiMSA)
Connect with Us
